Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Immusol to Collaborate on Cancer Drug Discovery

NEW YORK, June 22 (GenomeWeb News) - Immusol and Affymetrix have signed onto a scientific collaboration in which Immusol will use Affymetrix's gene chips in cancer drug discovery, the companies said today.


Under the collaboration, Immusol, of San Diego, will use Affymetrix's microarrays to conduct gene expression profiling on its engineered tumor cells, and identify pathways related to cancer. The program also aims to "acquire and validate additional therapeutic target candidates," the parties said. The scientists plan to obtain information about the molecular mechanism of actions of drugs or drug targets through perturbing the system and observing the results.


The parties did not disclose the financial terms of the agreement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.